In this conversation, my guest Simranjit Singh, CEO of Guardant Health in Singapore, discusses his journey in revolutionizing cancer diagnostics through precision oncology and liquid biopsies. He highlights the importance of early detection in bending mortality curves and the challenges faced in navigating diverse regulatory landscapes across Asia. The impact of COVID-19 on the perception of diagnostics is explored, along with advancements in early detection methods. Simran emphasizes the need for collaboration and adaptability in the evolving landscape of precision medicine in Asia.